A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : BsAb

Search Conditions:
Search Keyword : BsAb
Search Method : Exact match.
Research Area:

Abbreviation: BsAb
Appearance Frequency: 282 time(s)
Long forms: 9

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
bispecific antibody
(257 times)
(75 times)
mAb (14 times)
scFv (14 times)
EGFR (11 times)
1991 Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
bispecific monoclonal antibody
(11 times)
(5 times)
mAb (3 times)
ALL (2 times)
IL-2 (2 times)
1992 Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy.
bispecific Ab
(6 times)
Allergy and Immunology
(5 times)
CF (1 time)
CIK (1 time)
PA (1 time)
1997 Bispecific antibodies overcome the opsonin-receptor mismatch of cystic fibrosis in vitro: restoration of neutrophil-mediated phagocytosis and killing of Pseudomonas aeruginosa.
bispecific single-chain antibody
(3 times)
Complementary Therapies
(2 times)
CIK (1 time)
cpm (1 time)
FCM (1 time)
2000 A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
biospecific antibodies
(1 time)
Clinical Laboratory Techniques
(1 time)
Id (1 time)
MM (1 time)
PC (1 time)
1997 Membrane CD22 defines circulating myeloma-related cells as mature or later B cells.
bispecific anti-tumor/anti-DOTA-hapten antibody
(1 time)
(1 time)
CRs (1 time)
i.v (1 time)
MTD (1 time)
2020 Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses.
Bispecific monoclonal antibodies
(1 time)
(1 time)
--- 1995 Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Blinatumomab, thebispecificT cellengager antibody
(1 time)
Technology, Pharmaceutical
(1 time)
CHO (1 time)
EF1-alpha (1 time)
IRES (1 time)
2020 Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab.
CD3-bispecific antibody
(1 time)
(1 time)
hPBMC (1 time)
2019 A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.